Supplementary Figure 6 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 6. A. Drug naive and panobinostat and bortezomib-resistant (P + B) U87 cells were treated with gefitinib (2 µmol/L), enzastaurin (2 µmol/L), dasatinib (0.1 µmol/L), dinaciclib (0.18 µmol/L), PI 103 (1 µmol/L), PD 0325901 (2 µmol/L), HSP 990 (0.025 µmol/L), ABT 737 (2 µmol/L), JQ 1 (2 µmol/L), TP 0903 (2 µmol/L), Bay 11-7082 (2 µmol/L), YM 155 (0.025 µmol/L), cucurbitacin-I (0.2 µmol/L), vincristine (0.01 µmol/L), vinblastine (0.01 µmol/L), taxol (0.05 µmol/L), topotecan (0.025 µmol/L), temozolomide (25 µmol/L), gemcitabine (0.25 µmol/L) and 5-fluorouracil (20 µmol/L).
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362536294